NCT03544814 - EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

June 1, 2017

Study Completion Date

December 30, 2017

Conditions

Lung AdenocarcinomaEGFR Activating Mutation

Interventions

DRUG

icotinib combined with pemetrexed plus cisplatin

Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.

DRUG

first icotinib and then pemetrexed plus cisplatin

Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.

All Listed Sponsors

lead

Shanghai Chest Hospital

OTHER